Cited by 405Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsPancreatitis Pathology and Treatment

Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia

Open access
Singhi, Aatur D, McGrath, Kevin, Brand, Randall E, Khalid, Asif, Zeh, Herbert J, Chennat, Jennifer S, Fasanella, Kenneth E, Papachristou, Georgios I +13 more·2018·Gut

Abstract

Objective: DNA-based testing of pancreatic cyst fluid (PCF) is a useful adjunct to the evaluation of pancreatic cysts (PCs). Mutations in KRAS/GNAS are highly specific for intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs), while TP53/PIK3CA/PTEN alterations are associated with advanced neoplasia. A prospective study was performed to evaluate preoperative PCF DNA testing. Design: Over 43-months, 626 PCF specimens from 595 patients were obtained by endoscopic ultrasound (EUS)-fine needle aspiration and assessed by targeted next-generation sequencing (NGS). Molecular results were correlated with EUS findings, ancillary studies and follow-up. A separate cohort of 159 PCF specimens was also evaluated for KRAS/GNAS mutations by Sanger sequencing. Results: KRAS/GNAS mutations were identified in 308 (49%) PCs, while alterations in TP53/PIK3CA/PTEN were present in 35 (6%) cases. Based on 102 (17%) patients with surgical follow-up, KRAS/GNAS mutations were detected in 56 (100%) IPMNs and 3 (30%) MCNs, and associated with 89% sensitivity and 100% specificity for a mucinous PC. In comparison, KRAS/GNAS mutations by Sanger sequencing had a 65% sensitivity and 100% specificity. By NGS, the combination of KRAS/GNAS mutations and alterations in TP53/PIK3CA/PTEN had an 89% sensitivity and 100% specificity for advanced neoplasia. Ductal dilatation, a mural nodule and malignant cytopathology had lower sensitivities (42%, 32% and 32%, respectively) and specificities (74%, 94% and 98%, respectively). Conclusions: In contrast to Sanger sequencing, preoperative NGS of PCF for KRAS/GNAS mutations is highly sensitive for IPMNs and specific for mucinous PCs. In addition, the combination of TP53/PIK3CA/PTEN alterations is a useful preoperative marker for advanced neoplasia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2016-313586

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Blood remains the most commonly studied biospecimen for early detection, but many analytes are also present in other proximate samples, including pancreatic juice, stool, urine, saliva, and pancreatic cyst fluid.

    “In passing, it also needs to be stated that, although blood remains the most commonly studied biospecimen for early detection, many of the analytes are also present in other proximate samples, including pancreatic juice,53,54 stool,55 urine,56,57 saliva,58 and pancreatic cyst fluid.59”
  • Preliminary studies evaluating PIK3CA, SMAD4, and TP53 mutations in cyst fluid identified almost 80% of intraductal papillary mucinous neoplasms with high-grade dysplasia or cancer.

    “Preliminary studies evaluating the presence of mutations in PIK3CA, SMAD4, and TP53 in cyst fluid were promising, as they identified almost 80% of intraductal papillary mucinous neoplasms with high-grade dysplasia or cancer.43”

    From Early detection of pancreatic cancer (2020) · cites this paper as [43]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [28]Bosman FT, Carneiro F, Hruban RH Theise ND. World Health Organization (WHO) classification of tumours of the digestive system. Lyon, France: IARC Press, 2010.
  2. [29]Kakar S, Pawlik TM, Allen PJ, et al Amin MB, ed AJCC Cancer Staging Manual: Springer Nature, 2017.

Cited by

Sorted by citations

Authors
Singhi, A. D., McGrath, K., Brand, R. E., Khalid, A., Zeh, H. J., Chennat, J. S., Fasanella, K. E., Papachristou, G. I., Slivka, A., Bartlett, D. L., Dasyam, A. K., Hogg, M., Lee, K. K., Marsh, J. W., Monaco, S. E., Ohori, N. P., Pingpank, J. F., Tsung, A., Zureikat, A. H., Wald, A. I., & Nikiforova, M. N.
Affiliations
  • UPMC Health System (US)
  • University of Pittsburgh (US)
  • University of Pittsburgh Medical Center (US)
Corresponding author
Singhi, Aatur D
Venue
Gut
Publisher
BMJ
Published
2017-09-28
Volume
67
Issue
12
Pages
2131-2141
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2759917145
Cited by
405
References
32
Citations by year
2026: 41 · 2025: 44 · 2024: 46 · 2023: 48 · 2022: 42 · 2021: 68 · 2020: 43 · 2019: 46 · 2018: 26 · 2017: 1
FWCI
13.98
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Gut (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
Pancreatic Cancer Action Network
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
pancreatic cysts, pancreatic cyst fluid, KRAS mutation, GNAS mutation, intraductal papillary mucinous neoplasm, mucinous cystic neoplasm, TP53, PIK3CA, PTEN, advanced neoplasia, endoscopic ultrasound-guided fine-needle aspiration, cyst classification, diagnostic accuracy
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Chromogranins, DNA, Neoplasm, Female, Follow-Up Studies, Humans, Male, Middle Aged, Mutation, Neoplasm Proteins, Pancreatic Cyst, Pancreatic Neoplasms, Preoperative Care, Prospective Studies, Sensitivity and Specificity, Biomarkers, Tumor, Proto-Oncogene Proteins p21(ras), Neoplasms, Cystic, Mucinous, and Serous, GTP-Binding Protein alpha Subunits, Gs, Cyst Fluid, Carcinoma, Pancreatic Ductal, Young Adult, High-Throughput Nucleotide Sequencing, Endoscopic Ultrasound-Guided Fine Needle Aspiration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review